Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers

Pharmacology and Toxicology

Volumn 85, Issue 3, 1999, Pages 29-32

  Varis, Tiina ^a   Kivistö, Kari T ^a   Backman, Janne T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; HYDROCORTISONE; HYDROXYITRACONAZOLE; ITRACONAZOLE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032967254     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb01059.x     Document Type: Article

References (14)

1. Allenmark, S., A. Edebo & K. Lindgren: Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J. Chromatogr. 1990, 532, 203-206.
2. Ebling, W. F., S. J. Szefler & W. J. Jusko: Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis. J. Chromatogr. 1984, 305, 271-280.
3. Gibaldi, M. & D. Perrier: Pharmacokinetics. 2nd Ed. Marcel Dekker, New York, USA, 1982.
4. Jalava, K.-M., K. T. Olkkola & P. J. Neuvonen: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Therap. 1997, 61, 410-415.
5. Kivistö, K. T., T. S. Lamberg, T. Kantola & P. J. Neuvonen: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Therap. 1997, 62, 348-354.
6. Kurosawa, M., M. Okabe, N. Hara, K. Kawamura, S. Suzuki, K. Sakurada & M. Asaka: Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann. Hematol. 1996, 72, 17-21.
7. Neuvonen, P. J. & K.-M. Jalava: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Therap. 1996, 60, 54-61.
8. Olkkola, K. T., J. T. Backman & P. J. Neuvonen: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Therap. 1994, 55, 481-485.
9. Phillips, P., J. R. Graybill, R. Fetchick, & J. F. Dunn: Adrenal response to corticotropin during therapy with itraconazole. Antimicrob. Agents Chemother. 1987, 31, 647-649.
10. Queiroz-Telles, F., K. S. Purim, C. L. Boguszewski, F. C. Afonso & H. Graf: Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chromoblastomycosis. J. Antimicrob. Chemother. 1997, 40, 899- 902.
11. Saitoh, H., M. Hatakeyama, O. Eguchi, M. Oda & M. Takada: Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 1998, 87, 73-75.
12. Slayter, K. L., E. A. Ludwig, K. H. Lew, E. Middleton Jr., J. J. Ferry & W. J. Jusko: Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Therap. 1996, 59, 312-321.
13. Varhe, A., K. T. Olkkola & P. J. Neuvonen: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Therap. 1994, 56, 601-607.
14. Varis, T., K.-M. Kaukonen, K. T. Kivistö & P. J. Neuvonen: Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin. Pharmacol. Therap. 1998, 64, 363-368.